Avedro Announces Preparation for Anticipated Hyperopic Lasik Xtra® US Clinical Trial

Avedro Announces Preparation for Anticipated Hyperopic Lasik Xtra® US Clinical Trial

March 13, 2013

WALTHAM, Mass.--()--Avedro today announced that in preparation for its US clinical trial, a select group of US refractive surgeons have just completed Lasik Xtra procedure training under Gustavo Tamayo, MD, at the Bogota Laser Center in Bogota, Colombia.

Acceleron Initiates Phase 2 Study of ACE-536 to Treat Patients with Beta-Thalassemia

Acceleron Initiates Phase 2 Study of ACE-536 to Treat Patients with Beta-Thalassemia

March 7, 2013

Novel biologic has potential to treat rare blood disorder with substantial unmet medical need

Receptos Determines Novel GPCR Structure, Achieves Key Milestone in Collaboration with Ono Pharmaceuticals

Receptos Determines Novel GPCR Structure, Achieves Key Milestone in Collaboration with Ono Pharmaceuticals

March 7, 2013

SAN DIEGO, March 7, 2013 /PRNewswire/ -- Receptos, a biopharmaceutical company focused on developing therapeutic candidates directed to G-protein-coupled receptor (GPCR) targets, announced today that it has successfully determined a novel protein crystal structure of an undisclosed proprietary GPCR drug discovery target for Ono Pharmaceuticals.

BG Medicine Highlights Role of Galectin-3 Testing in Combating Hospital Readmissions at the American College of Cardiology's (ACC) 62nd Annual Scientific Session & Expo

BG Medicine Highlights Role of Galectin-3 Testing in Combating Hospital Readmissions at the American College of Cardiology's (ACC) 62nd Annual Scientific Session & Expo

March 6, 2013

WALTHAM, Mass., March 6, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc.

Avedro Completes $43 Million Series D Financing

Avedro Completes $43 Million Series D Financing

March 5, 2013

WALTHAM, Mass., Mar 05, 2013 (BUSINESS WIRE) -- Avedro, Inc. announced today the completion of a $43 million Series D financing led by Abingworth along with a significant investment by Third Point. Avedro's other investors include Prism Venture Works, De Novo Ventures, Flagship Ventures, Aperture Ventures, SCP Vitalife Partners, Borealis Ventures and Echelon Ventures.

As part of the transaction, David Mayer from Abingworth and Jason Hong, PhD from Third Point will be joining the Board of Directors.

David Edwards's WikiCell Makes Edible Food Packaging

David Edwards's WikiCell Makes Edible Food Packaging

February 28, 2013

A third of the waste that’s dumped into landfills is packaging such as boxes, bags, and food wrappers. David Edwards has a solution: Just eat it.

Last year, Edwards, 51, a bioengineer at Harvard, launched WikiCell, which makes edible packaging for everything from yogurt to coffee and even alcoholic drinks. “We can basically surround any food or beverage with a skin like a grape skin that’s fully edible, and then consume it,” he says. Picture a martini wrapped in an olive that you can stick in your pocket and rinse off when you’re ready for a toast.

The NEXT Next Big Thing

The NEXT Next Big Thing

February 27, 2013

In December, Moderna Therapeutics announced that it had pioneered a technology that would revolutionize the practice of medicine and disrupt the pharmaceutical industry. But biotech startups have been making similar promises for decades, and the revolution has yet to arrive. Can Moderna really pull off what countless others have not?

BG Medicine, Inc. Announces Publication of Two Studies Supporting Repeat Galectin-3 Testing in Heart Failure Patients

BG Medicine, Inc. Announces Publication of Two Studies Supporting Repeat Galectin-3 Testing in Heart Failure Patients

February 27, 2013

WALTHAM, Mass., Feb 27, 2013 (Menafn - GLOBE NEWSWIRE via COMTEX) --BG Medicine, Inc. BGMD, a diagnostics company focused on the development and commercialization of novel cardiovascular tests, announced today the publication of two studies demonstrating the clinical utility of repeated galectin-3 testing as a tool in the assessment of patients with heart failure.

Jazz Pharmaceuticals plc and Concert Pharmaceuticals Announce Worldwide Licensing Agreement to Develop and Commercialize Deuterium-Modified Sodium Oxybate

Jazz Pharmaceuticals plc and Concert Pharmaceuticals Announce Worldwide Licensing Agreement to Develop and Commercialize Deuterium-Modified Sodium Oxybate

February 26, 2013

DUBLIN and LEXINGTON, Mass., Feb 26, 2013 (BUSINESS WIRE) -- Jazz Pharmaceuticals plc and Concert Pharmaceuticals, Inc. today announced an exclusive license agreement that provides Jazz Pharmaceuticals worldwide rights to develop and commercialize Concert's deuterium-modified sodium oxybate (D-SXB) compounds, including C-10323.

Seahorse Bioscience XF Technology Yields Insights on Leukemia Stem Cell Metabolism and Potential New Leukemia Therapies

Seahorse Bioscience XF Technology Yields Insights on Leukemia Stem Cell Metabolism and Potential New Leukemia Therapies

February 22, 2013

500th XF Data Reference in Elsevier: Cell Stem Cell

Billerica, MA, February 22, 2013 – Seahorse Bioscience, the world leader in instruments and assay kits for measuring cell metabolism, announced a new milestone: the 500th journal reference including XF assay data. The paper, titled BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells, will be published in the March 7, 2013 issue of the journal Cell Stem Cell.